Bone Biologics appoints Robert Gagnon to board of directors, replacing Erick Lucera

Bone Biologics Corp

Robert Gagnon appointed to board effective Jan 8, 2024; Erick Lucera resigned same date.
Gagnon will chair audit committee and serve on compensation and nominating committees.
He brings 20+ years finance experience; currently CFO of Remix Therapeutics.
Board size remains at four members after appointment.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert E. Gagnon

Director

BBLG · Bone Biologics Corp

Effective: 2024-01-08
Filed: January 11, 2024, 6:59 PM ET

On January 8, 2024, the Board of Directors of Bone Biologics Corporation (the “Company”) appointed Robert E. Gagnon to the Company’s Board of Directors.

Departed

Erick Lucera

Director

BBLG · Bone Biologics Corp

Effective: 2024-01-08
Successor: Robert E. Gagnon
Filed: January 11, 2024, 6:59 PM ET

As previously disclosed, Erick Lucera resigned from the Board of Directors on December 27, 2023, effective as of the date Mr. Gagnon was appointed.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert E. Gagnon was appointed as Director at Bone Biologics Corp.

Action: appointed
Role: Director

Exact text from the filing

On January 8, 2024, the Board of Directors of Bone Biologics Corporation (the “Company”) appointed Robert E. Gagnon to the Company’s Board of Directors.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Erick Lucera resigned as Director at Bone Biologics Corp.

Action: resigned
Role: Director

Exact text from the filing

As previously disclosed, Erick Lucera resigned from the Board of Directors on December 27, 2023, effective as of the date Mr. Gagnon was appointed.

View on SEC.gov

Bone Biologics Corp filing history →

Source: SEC EDGAR

accession 0001493152-24-002010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.